The off-label use of semaglutide, a GLP-1 receptor agonist initially developed for type 2 diabetes treatment, for weight loss in non-diabetic individuals has raised significant concerns among healthcare professionals and regulators. Although semaglutide effectively reduces body weight, its use in individuals without diabetes carries risks and ethical challenges.
Semaglutide mimics the natural hormone GLP-1, which controls appetite and insulin secretion. Clinical trials have demonstrated notable weight loss—up to 14.9% body weight reduction over 68 weeks. However, these studies were conducted in specific populations, and long-term effects in non-diabetic users remain uncertain.
Singapore’s Health Sciences Authority (HSA) has voiced concerns about prescription drug misuse. In response to rising demand for drugs like Ozempic and Wegovy for weight loss, the Ministry of Health (MOH) has implemented measures to ensure these drugs are obtained only for their approved medical purposes. The MOH collaborates with healthcare institutions and pharmaceutical companies to monitor usage patterns domestically and internationally, aiming to minimize treatment disruption and maintain drug supply stability. Such ongoing oversight and regulation are vital to protect public health and uphold the integrity of approved medical treatments.